AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8015776 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-aided drainage using an angulated endolaser probe set at 1 W for 0.2 seconds, average of 2.4 laser burns
Number of subjects: 50
Study 8015776 — intervention group
Group type: COMPARATOR
Intervention: Transchoroidal needle drainage
Number of subjects: 50
Study 2513741 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.015 mg/kg IV)
Number of subjects: 21
Study 2513741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29731406 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promoting Conversations intervention
Number of subjects: 17
Study 29731406 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 29231605 — intervention group
Group type: EXPERIMENTAL
Intervention: qi‐conducting needling technique at the governor vessel acupoints combined with electroacupuncture (EA)
Number of subjects: 201
Study 29231605 — intervention group
Group type: COMPARATOR
Intervention: Conventional electroacupuncture (EA)
Number of subjects: 201
Study 24285491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early metacarpal bone mineral density (BMD) loss after 4 months of treatment
Number of subjects: 610
Study 24285491 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of baseline erosions
Number of subjects: 610
Study 24285491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early metacarpal BMD loss in patients without baseline erosions
Number of subjects: 610
Study 24285491 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological progression after 1 year
Number of subjects: 610
Study 23645236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (137.5 mg/d)
Number of subjects: 260
Study 23645236 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (19.5 mg/d)
Number of subjects: 260
Study 21915616 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum total cholesterol (≥240 mg/dl)
Number of subjects: 29093
Study 21915616 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HDL cholesterol
Number of subjects: 29093
Study 18355139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ho:YAG laser
Number of subjects: 50
Study 18355139 — intervention group
Group type: COMPARATOR
Intervention: LithoClast 2
Number of subjects: 50
Study 16832617 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 39
Study 16832617 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (in methane producers)
Number of subjects: 39
Study 16832617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16832617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in methane producers)
Number of subjects: 39
Study 12605618 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infusion (RI) of 150 mg thiamine over 1 hour
Number of subjects: 12
Study 12605618 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion (SI) of 150 mg thiamine over 24 hours
Number of subjects: 12
Study 10848859 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP (Transabdominal Preperitoneal)
Number of subjects: 91
Study 10848859 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 91
Study 9356537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil treatment (20 g fish oil/d)
Number of subjects: 15
Study 9356537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil treatment with increased fiber intake (15 g pectin supplement)
Number of subjects: 15
Study 9356537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil treatment with increased fiber intake
Number of subjects: 15
Study 1607194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 5 days (treated partners)
Number of subjects: 54
Study 1607194 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated partners)
Number of subjects: 54
Study 3896609 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group I)
Number of subjects: 90
Study 3896609 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Group II)
Number of subjects: 90
Study 30983049 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation with point‐by‐point radiofrequency energy
Number of subjects: 0
Study 30983049 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation with cryoballoon technology
Number of subjects: 0
Study 30983049 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 0
Study 30983049 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban for periprocedural oral anticoagulation
Number of subjects: 0
Study 30983049 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging integration with cardiac magnetic resonance or computed tomography
Number of subjects: 0
Study 30204689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 254
Study 30204689 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone (200 mg/24 hours)
Number of subjects: 254
Study 27435280 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CROSS protocol: 41.4Gy plus carboplatin/paclitaxel) followed by surgery
Number of subjects: 438
Study 27435280 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) followed by surgery
Number of subjects: 438
Study 27435280 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CROSS protocol)
Number of subjects: 438
Study 27435280 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (FLOT protocol)
Number of subjects: 438
Study 25118116 — intervention group
Group type: EXPERIMENTAL
Intervention: High pulse pressure (>40 mm Hg)
Number of subjects: 754
Study 25118116 — intervention group
Group type: COMPARATOR
Intervention: Low pulse pressure (≤40 mm Hg)
Number of subjects: 754
Study 22371836 — intervention group
Group type: EXPERIMENTAL
Intervention: Clips (group I)
Number of subjects: 30
Study 22371836 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone resilient liners (group II)
Number of subjects: 30
Study 20534147 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (18-week supervised group exercise programme)
Number of subjects: 300
Study 20534147 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintain habitual physical activity pattern)
Number of subjects: 300
Study 20534147 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 300
Study 18577410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria CRM(197)‐based Haemophilus influenzae type b conjugate vaccine (HbOC)
Number of subjects: 0
Study 18577410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria CRM(197)‐based combination 9‐valent pneumococcal conjugate vaccine/meningococcal group C conjugate vaccine
Number of subjects: 0
Study 16238663 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-mediated intervention
Number of subjects: 0
Study 16238663 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12454841 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 70
Study 12454841 — intervention group
Group type: COMPARATOR
Intervention: Repeated paracentesis plus intravenous albumin
Number of subjects: 70
Study 10321658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, maximum 800 mg, administered intravenously over 30 to 60 mins every 6 hrs for eight doses)
Number of subjects: 455
Study 10321658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine buffer vehicle)
Number of subjects: 455
Study 8755119 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression in tumor cells
Number of subjects: 101
Study 8755119 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression in tumor cells with mucosal invasion
Number of subjects: 101
Study 8755119 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression in tumor cells with submucosal invasion
Number of subjects: 101
Study 8755119 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VEGF expression and tumor progression
Number of subjects: 101
Study 1722793 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg/day for 6 months)
Number of subjects: 43
Study 1722793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7042699 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline, 150 mg/day
Number of subjects: 0
Study 7042699 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine, 60 mg/day
Number of subjects: 0
Study 30865730 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Case Finding (ACF)
Number of subjects: 465
Study 30865730 — intervention group
Group type: COMPARATOR
Intervention: Passive Case Finding (PCF)
Number of subjects: 465
Study 28776105 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention delivered by Maternal and Child Health Nurses (MCHNs), n = 20
Number of subjects: 541
Study 28776105 — intervention group
Group type: COMPARATOR
Intervention: Routine Care, n = 20
Number of subjects: 541
Study 28776105 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 541
Study 25993251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax appliance
Number of subjects: 33
Study 25993251 — intervention group
Group type: COMPARATOR
Intervention: Haas appliance
Number of subjects: 33
Study 25993251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-expansion to post-expansion root volumes
Number of subjects: 33
Study 25993251 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of root volume loss
Number of subjects: 33
Study 25993251 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric changes after 6 months of retention
Number of subjects: 33
Study 24338901 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D T2prep-GRE
Number of subjects: 0
Study 24338901 — intervention group
Group type: COMPARATOR
Intervention: 2D spin-echo EPI
Number of subjects: 0
Study 21134950 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal multi-faceted strategy (professional and patient oriented)
Number of subjects: 1499
Study 21134950 — intervention group
Group type: COMPARATOR
Intervention: Minimal professional-oriented implementation strategy (audit and feedback)
Number of subjects: 1499
Study 18951682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 111
Study 18951682 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 18951682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (early group)
Number of subjects: 111
Study 18951682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (longer group)
Number of subjects: 111
Study 17230055 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiogel AI cream
Number of subjects: 0
Study 14715560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV)
Number of subjects: 67
Study 14715560 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 67
Study 11248824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 0.3% ophthalmic solution
Number of subjects: 217
Study 11248824 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 0.3% ophthalmic solution
Number of subjects: 217
Study 9215245 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler
Number of subjects: 217
Study 9215245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate Diskhaler
Number of subjects: 217
Study 7517181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin 75 mg
Number of subjects: 164
Study 7517181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 3691943 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispatula
Number of subjects: 236
Study 3691943 — intervention group
Group type: COMPARATOR
Intervention: Ayre spatula
Number of subjects: 236
Study 31863505 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (0.1 or 0.2 mg/kg)
Number of subjects: 6
Study 31863505 — intervention group
Group type: EXPERIMENTAL
Intervention: Acepromazine (0.02 or 0.04 mg/kg)
Number of subjects: 6
Study 31863505 — intervention group
Group type: EXPERIMENTAL
Intervention: Local analgesia (4 mL 2% mepivacaine administered subcutaneously)
Number of subjects: 6
Study 31863505 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (1 mL)
Number of subjects: 6
Study 30219460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Therapy (DT)
Number of subjects: 13
Study 30219460 — intervention group
Group type: COMPARATOR
Intervention: Support group (control)
Number of subjects: 13
Study 26728931 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred and activity-oriented intervention program
Number of subjects: 168
Study 26728931 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 24178750 — intervention group
Group type: EXPERIMENTAL
Intervention: IV G‐CSF (5 mcg/kg single daily dose)
Number of subjects: 120
Study 24178750 — intervention group
Group type: COMPARATOR
Intervention: SC G‐CSF (filgrastim)
Number of subjects: 120
Study 24178750 — intervention group
Group type: EXPERIMENTAL
Intervention: IV G‐CSF
Number of subjects: 120
Study 24178750 — intervention group
Group type: COMPARATOR
Intervention: SC G‐CSF
Number of subjects: 120
Study 24178750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IV and SC G‐CSF
Number of subjects: 120
Study 22864282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg q.d.)
Number of subjects: 471
Study 22864282 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg b.i.d.)
Number of subjects: 471
Study 19115106 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd-line hormone therapy
Number of subjects: 224
Study 17661962 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (mailing an antibiotic guide and prescribing profile)
Number of subjects: 36
Study 17661962 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 36
Study 17661962 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (postintervention II)
Number of subjects: 36
Study 15953681 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma (colloid)
Number of subjects: 20
Study 15953681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine (colloid)
Number of subjects: 20
Study 12381426 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 391
Study 12381426 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 391
Study 9987516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance alone (Regimen I)
Number of subjects: 200
Study 9987516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance plus the eating of wheat bran biscuits (Regimen II)
Number of subjects: 200
Study 7750667 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 12
Study 7750667 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole
Number of subjects: 12
Study 7750667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2081866 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 135
Study 2081866 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 135
Study 582985 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg in customary preparation (A 300)
Number of subjects: 5
Study 582985 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg in slow-release preparation (A ret)
Number of subjects: 5
Study 31350643 — intervention group
Group type: EXPERIMENTAL
Intervention: SCEV group (n=39)
Number of subjects: 78
Study 31350643 — intervention group
Group type: COMPARATOR
Intervention: Control group without visualization (n=39)
Number of subjects: 78
Study 31058714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trios-OSCE training
Number of subjects: 3
Study 31058714 — intervention group
Group type: COMPARATOR
Intervention: Regular OSCE training
Number of subjects: 3
Study 31058714 — intervention group
Group type: COMPARATOR
Intervention: Control group (OSCE observers)
Number of subjects: 3
Study 28586888 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based testing and treatment intervention
Number of subjects: 77774
Study 25034118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine/Phenylalanine depletion
Number of subjects: 103
Study 25034118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 103
Study 25034118 — intervention group
Group type: COMPARATOR
Intervention: Control group (balanced amino acid drink)
Number of subjects: 103
Study 23486858 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-radial (TR) approach
Number of subjects: 1668
Study 23486858 — intervention group
Group type: COMPARATOR
Intervention: Trans-femoral (TF) approach
Number of subjects: 1668
Study 21843115 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of COPD
Number of subjects: 445
Study 21843115 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patient age
Number of subjects: 445
Study 21843115 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of comorbidities
Number of subjects: 445
Study 19666358 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: Paracetamol suppository at a dose of 15 mg/kg
Number of subjects: 202
Study 19666358 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B: Niflumique acid suppository at a dose of 13 mg/kg
Number of subjects: 202
Study 19666358 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C: Combination of paracetamol (15 mg/kg) and niflumique acid (13 mg/kg)
Number of subjects: 202
Study 16170976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride gel‐releasing interdental brush (IDB)
Number of subjects: 162
Study 16170976 — intervention group
Group type: COMPARATOR
Intervention: Standard flossing regimen (positive control)
Number of subjects: 162
Study 16170976 — intervention group
Group type: COMPARATOR
Intervention: Standard tooth brushing only regimen (control)
Number of subjects: 162
Study 16170976 — intervention group
Group type: EXPERIMENTAL
Intervention: Other IDB groups (not specified)
Number of subjects: 162
Study 11836799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (5 sessions of 30-min duration per week)
Number of subjects: 0
Study 11836799 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (exercising upper and lower limbs against a graded resistance machine)
Number of subjects: 0
Study 11836799 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard chest physiotherapy)
Number of subjects: 0
Study 10530266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 48
Study 10530266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 48
Study 10530266 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 48
Study 10530266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7727330 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0 micrograms
Number of subjects: 60
Study 7727330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms
Number of subjects: 60
Study 7727330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 60
Study 2252045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg on alternate days)
Number of subjects: 21738
Study 2252045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21738
Study 7017177 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levodopa and benserazide
Number of subjects: 47
Study 7017177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31712331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical ERAS protocol
Number of subjects: 140
Study 31712331 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative care (control group)
Number of subjects: 140
Study 28483221 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental external nasal dilator (END)
Number of subjects: 65
Study 28483221 — intervention group
Group type: COMPARATOR
Intervention: Placebo external nasal dilator (END)
Number of subjects: 65
Study 24832461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding within 30 days after PCI
Number of subjects: 14180
Study 24832461 — intervention group
Group type: COMPARATOR
Intervention: No bleeding within 30 days after PCI
Number of subjects: 14180
Study 24832461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding between 30 days to 1 year after PCI
Number of subjects: 14180
Study 24832461 — intervention group
Group type: COMPARATOR
Intervention: No bleeding between 30 days to 1 year after PCI
Number of subjects: 14180
Study 21118900 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 3354
Study 21118900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3354
Study 19824560 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio bonded with Solobond (n=36)
Number of subjects: 30
Study 19824560 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram bonded with Syntac (n=32)
Number of subjects: 30
Study 16739327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative IL-2 immunotherapy (6x10(6) I.U. twice daily for 3 days)
Number of subjects: 86
Study 16739327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IL-2 treatment)
Number of subjects: 86
Study 16739327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative IL-2 immunotherapy in Dukes' B patients
Number of subjects: 86
Study 16739327 — intervention group
Group type: COMPARATOR
Intervention: Control group for Dukes' B patients
Number of subjects: 86
Study 16739327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative IL-2 immunotherapy in Dukes' C patients
Number of subjects: 86
Study 16739327 — intervention group
Group type: COMPARATOR
Intervention: Control group for Dukes' C patients
Number of subjects: 86
Study 15616339 — intervention group
Group type: EXPERIMENTAL
Intervention: MAALOX TC
Number of subjects: 2